1
|
Gerszberg A, Hnatuszko-Konka K. Compendium on Food Crop Plants as a Platform for Pharmaceutical Protein Production. Int J Mol Sci 2022; 23:3236. [PMID: 35328657 PMCID: PMC8951019 DOI: 10.3390/ijms23063236] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/27/2022] [Revised: 03/14/2022] [Accepted: 03/15/2022] [Indexed: 12/14/2022] Open
Abstract
Tremendous advances in crop biotechnology related to the availability of molecular tools and methods developed for transformation and regeneration of specific plant species have been observed. As a consequence, the interest in plant molecular farming aimed at producing the desired therapeutic proteins has significantly increased. Since the middle of the 1980s, recombinant pharmaceuticals have transformed the treatment of many serious diseases and nowadays are used in all branches of medicine. The available systems of the synthesis include wild-type or modified mammalian cells, plants or plant cell cultures, insects, yeast, fungi, or bacteria. Undeniable benefits such as well-characterised breeding conditions, safety, and relatively low costs of production make plants an attractive yet competitive platform for biopharmaceutical production. Some of the vegetable plants that have edible tubers, fruits, leaves, or seeds may be desirable as inexpensive bioreactors because these organs can provide edible vaccines and thus omit the purification step of the final product. Some crucial facts in the development of plant-made pharmaceuticals are presented here in brief. Although crop systems do not require more strictly dedicated optimization of methodologies at any stages of the of biopharmaceutical production process, here we recall the complete framework of such a project, along with theoretical background. Thus, a brief review of the advantages and disadvantages of different systems, the principles for the selection of cis elements for the expression cassettes, and available methods of plant transformation, through to the protein recovery and purification stage, are all presented here. We also outline the achievements in the production of biopharmaceuticals in economically important crop plants and provide examples of their clinical trials and commercialization.
Collapse
Affiliation(s)
- Aneta Gerszberg
- Department of Molecular Biotechnology and Genetics, Faculty of Biology and Environmental Protection, University of Lodz, Banacha 12/16, 90-237 Lodz, Poland
| | - Katarzyna Hnatuszko-Konka
- Department of Molecular Biotechnology and Genetics, Faculty of Biology and Environmental Protection, University of Lodz, Banacha 12/16, 90-237 Lodz, Poland
| |
Collapse
|
2
|
Improving Protein Quantity and Quality—The Next Level of Plant Molecular Farming. Int J Mol Sci 2022; 23:ijms23031326. [PMID: 35163249 PMCID: PMC8836236 DOI: 10.3390/ijms23031326] [Citation(s) in RCA: 11] [Impact Index Per Article: 5.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/26/2021] [Revised: 01/21/2022] [Accepted: 01/22/2022] [Indexed: 12/15/2022] Open
Abstract
Plants offer several unique advantages in the production of recombinant pharmaceuticals for humans and animals. Although numerous recombinant proteins have been expressed in plants, only a small fraction have been successfully put into use. The hugely distinct expression systems between plant and animal cells frequently cause insufficient yield of the recombinant proteins with poor or undesired activity. To overcome the issues that greatly constrain the development of plant-produced pharmaceuticals, great efforts have been made to improve expression systems and develop alternative strategies to increase both the quantity and quality of the recombinant proteins. Recent technological revolutions, such as targeted genome editing, deconstructed vectors, virus-like particles, and humanized glycosylation, have led to great advances in plant molecular farming to meet the industrial manufacturing and clinical application standards. In this review, we discuss the technological advances made in various plant expression platforms, with special focus on the upstream designs and milestone achievements in improving the yield and glycosylation of the plant-produced pharmaceutical proteins.
Collapse
|
3
|
McNulty MJ, Xiong YM, Yates K, Karuppanan K, Hilzinger JM, Berliner AJ, Delzio J, Arkin AP, Lane NE, Nandi S, McDonald KA. Molecular pharming to support human life on the moon, mars, and beyond. Crit Rev Biotechnol 2021; 41:849-864. [PMID: 33715563 DOI: 10.1080/07388551.2021.1888070] [Citation(s) in RCA: 12] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/20/2022]
Abstract
Space missions have always assumed that the risk of spacecraft malfunction far outweighs the risk of human system failure. This assumption breaks down for longer duration exploration missions and exposes vulnerabilities in space medical systems. Space agencies can no longer reduce the majority of the human health and performance risks through crew members selection process and emergency re-supply or evacuation. No mature medical solutions exist to address this risk. With recent advances in biotechnology, there is promise for lessening this risk by augmenting a space pharmacy with a biologically-based space foundry for the on-demand manufacturing of high-value medical products. Here we review the challenges and opportunities of molecular pharming, the production of pharmaceuticals in plants, as the basis of a space medical foundry to close the risk gap in current space medical systems. Plants have long been considered to be an important life support object in space and can now also be viewed as programmable factories in space. Advances in molecular pharming-based space foundries will have widespread applications in promoting simple and accessible pharmaceutical manufacturing on Earth.
Collapse
Affiliation(s)
- Matthew J McNulty
- Center for the Utilization of Biological Engineering in Space (CUBES), Berkeley, CA, USA.,Department of Chemical Engineering, University of California, Davis, CA, USA
| | - Yongao Mary Xiong
- Center for the Utilization of Biological Engineering in Space (CUBES), Berkeley, CA, USA.,Department of Chemical Engineering, University of California, Davis, CA, USA
| | - Kevin Yates
- Center for the Utilization of Biological Engineering in Space (CUBES), Berkeley, CA, USA.,Department of Chemical Engineering, University of California, Davis, CA, USA
| | - Kalimuthu Karuppanan
- Center for the Utilization of Biological Engineering in Space (CUBES), Berkeley, CA, USA.,Radcliffe Department of Medicine, Oxford University, Oxford, UK
| | - Jacob M Hilzinger
- Center for the Utilization of Biological Engineering in Space (CUBES), Berkeley, CA, USA.,Department of Bioengineering, University of California, Berkeley, CA, USA
| | - Aaron J Berliner
- Center for the Utilization of Biological Engineering in Space (CUBES), Berkeley, CA, USA.,Department of Bioengineering, University of California, Berkeley, CA, USA
| | - Jesse Delzio
- Center for the Utilization of Biological Engineering in Space (CUBES), Berkeley, CA, USA.,Department of Chemical Engineering, University of California, Davis, CA, USA
| | - Adam P Arkin
- Center for the Utilization of Biological Engineering in Space (CUBES), Berkeley, CA, USA.,Department of Bioengineering, University of California, Berkeley, CA, USA
| | - Nancy E Lane
- Center for Musculoskeletal Health, School of Medicine, University of California, Davis, CA, USA
| | - Somen Nandi
- Center for the Utilization of Biological Engineering in Space (CUBES), Berkeley, CA, USA.,Department of Chemical Engineering, University of California, Davis, CA, USA.,Global HealthShare® Initiative, University of California, Davis, CA, USA
| | - Karen A McDonald
- Center for the Utilization of Biological Engineering in Space (CUBES), Berkeley, CA, USA.,Department of Chemical Engineering, University of California, Davis, CA, USA.,Global HealthShare® Initiative, University of California, Davis, CA, USA
| |
Collapse
|
4
|
Ramos-Vega A, Monreal-Escalante E, Dumonteil E, Bañuelos-Hernández B, Angulo C. Plant-made vaccines against parasites: bioinspired perspectives to fight against Chagas disease. Expert Rev Vaccines 2021; 20:1373-1388. [PMID: 33612044 DOI: 10.1080/14760584.2021.1893170] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/18/2022]
Abstract
Introduction: Three decades of evidence have demonstrated that plants are an affordable platform for biopharmaceutical production and delivery. For instance, several plant-made recombinant proteins have been approved for commercialization under good manufacturing practice (GMP). Thus far, plant-based vaccine prototypes have been evaluated at pre- and clinical levels. Particularly, plant-made vaccines against parasitic diseases, such as malaria, cysticercosis, and toxoplasmosis have been successfully produced and orally delivered with promising outcomes in terms of immunogenicity and protection. The experience on several approaches and technical strategies over 30 years accounts for their potential low-cost, high scalability, and easy administration.Areas covered: This platform is an open technology to fight against Chagas disease, one of the most important neglected tropical diseases worldwide.Expert opinion: This review provides a perspective for the potential use of plants as a production platform and delivery system of Trypanosoma cruzi recombinant antigens, analyzing the advantages and limitations with respect to plant-made vaccines produced for other parasitic diseases. Plant-made vaccines are envisioned to fight against Chagas disease and other neglected tropical diseases in those countries suffering endemic prevalence.
Collapse
Affiliation(s)
- Abel Ramos-Vega
- Grupo de Inmunología & Vacunología. Centro de Investigaciones Biológicas del Noroeste, S.C. (CIBNOR), Instituto Politécnico Nacional 195, Playa Palo de Santa Rita Sur, La Paz, B.c.s. C.p., México
| | - Elizabeth Monreal-Escalante
- Grupo de Inmunología & Vacunología. Centro de Investigaciones Biológicas del Noroeste, S.C. (CIBNOR), Instituto Politécnico Nacional 195, Playa Palo de Santa Rita Sur, La Paz, B.c.s. C.p., México.,CONACYT- Centro de Investigaciones Biológicas del Noroeste, S.C. (CIBNOR), Instituto Politécnico Nacional 195, Playa Palo de Santa Rita Sur, La Paz, B.c.s. C.p, México
| | - Eric Dumonteil
- Department of Tropical Medicine, School of Public Health and Tropical Medicine, and Vector-Borne and Infectious Disease Research Center, Tulane University, New Orleans, LA, USA
| | - Bernardo Bañuelos-Hernández
- Facultad de Agronomía Y Veterinaria, Universidad de La Salle Bajio, Avenida Universidad 602, Lomas del Campestre, León Guanajuato, México
| | - Carlos Angulo
- Grupo de Inmunología & Vacunología. Centro de Investigaciones Biológicas del Noroeste, S.C. (CIBNOR), Instituto Politécnico Nacional 195, Playa Palo de Santa Rita Sur, La Paz, B.c.s. C.p., México
| |
Collapse
|
5
|
Temporini C, Colombo R, Calleri E, Tengattini S, Rinaldi F, Massolini G. Chromatographic tools for plant-derived recombinant antibodies purification and characterization. J Pharm Biomed Anal 2020; 179:112920. [DOI: 10.1016/j.jpba.2019.112920] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/28/2019] [Revised: 10/04/2019] [Accepted: 10/09/2019] [Indexed: 01/13/2023]
|
6
|
Pyrski M, Mieloch AA, Plewiński A, Basińska-Barczak A, Gryciuk A, Bociąg P, Murias M, Rybka JD, Pniewski T. Parenteral-Oral Immunization with Plant-Derived HBcAg as a Potential Therapeutic Vaccine against Chronic Hepatitis B. Vaccines (Basel) 2019; 7:E211. [PMID: 31835350 PMCID: PMC6963566 DOI: 10.3390/vaccines7040211] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/18/2019] [Revised: 12/02/2019] [Accepted: 12/06/2019] [Indexed: 12/16/2022] Open
Abstract
Chronic hepatitis B (CHB) is the cause of severe liver damage, cirrhosis, and hepatocellular carcinoma for over 240 million people worldwide. Nowadays, several types of treatment are being investigated, including immunotherapy using hepatitis B core antigen (HBcAg) assembled into highly immunogenic capsid-like particles (CLPs). Immunogenicity of plant-produced and purified HBcAg, administered parenterally or intranasally, was previously reported. In this study, a novel parenteral-oral vaccination scheme is proposed using plant-derived HBcAg preparations. The antigen for injection was obtained via transient expression in Nicotiana benthamiana. HBcAg-producing transgenic lettuce was lyophilized and used as an orally delivered booster. The intracellular location of plant-produced HBcAg CLPs implies additional protection in the digestive tract during oral immunization. BALB/c mice were intramuscularly primed with 10 µg of the purified antigen and orally boosted twice with 5 or 200 ng of HBcAg. A long-lasting and significant systemic response after boosting with 200 ng HBcAg was induced, with anti-HBc titer of 25,000. Concomitantly, an insignificant mucosal response was observed, with an S-IgA titer of only 500. The profile of IgG isotypes indicates a predominant Th1 type of immune response, supplemented by Th2, after injection-oral vaccination. The results demonstrate that a low dose of parenteral-oral immunization with plant-derived HBcAg can elicit a specific and efficient response. This study presents a potential new pathway of CHB treatment.
Collapse
Affiliation(s)
- Marcin Pyrski
- Institute of Plant Genetics, Polish Academy of Sciences, Strzeszyńska 34, 60-479 Poznań, Poland; (M.P.); (A.B.-B.); (A.G.); (P.B.)
| | - Adam Aron Mieloch
- Center for Advanced Technology, Adam Mickiewicz University, Uniwersytetu Poznańskiego 10, 61-614 Poznań, Poland; (A.A.M.); (A.P.)
- Faculty of Chemistry, Adam Mickiewicz University, Uniwersytetu Poznańskiego 8, 61-614 Poznań, Poland
| | - Adam Plewiński
- Center for Advanced Technology, Adam Mickiewicz University, Uniwersytetu Poznańskiego 10, 61-614 Poznań, Poland; (A.A.M.); (A.P.)
| | - Aneta Basińska-Barczak
- Institute of Plant Genetics, Polish Academy of Sciences, Strzeszyńska 34, 60-479 Poznań, Poland; (M.P.); (A.B.-B.); (A.G.); (P.B.)
| | - Aleksandra Gryciuk
- Institute of Plant Genetics, Polish Academy of Sciences, Strzeszyńska 34, 60-479 Poznań, Poland; (M.P.); (A.B.-B.); (A.G.); (P.B.)
| | - Piotr Bociąg
- Institute of Plant Genetics, Polish Academy of Sciences, Strzeszyńska 34, 60-479 Poznań, Poland; (M.P.); (A.B.-B.); (A.G.); (P.B.)
| | - Marek Murias
- Department of Toxicology, Poznan University of Medical Sciences, Dojazd 30, 60-631 Poznań, Poland;
| | - Jakub Dalibor Rybka
- Center for Advanced Technology, Adam Mickiewicz University, Uniwersytetu Poznańskiego 10, 61-614 Poznań, Poland; (A.A.M.); (A.P.)
| | - Tomasz Pniewski
- Institute of Plant Genetics, Polish Academy of Sciences, Strzeszyńska 34, 60-479 Poznań, Poland; (M.P.); (A.B.-B.); (A.G.); (P.B.)
| |
Collapse
|
7
|
Kopertekh L, Schiemann J. Transient Production of Recombinant Pharmaceutical Proteins in Plants: Evolution and Perspectives. Curr Med Chem 2019; 26:365-380. [DOI: 10.2174/0929867324666170718114724] [Citation(s) in RCA: 32] [Impact Index Per Article: 6.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/30/2017] [Revised: 06/07/2017] [Accepted: 06/07/2017] [Indexed: 11/22/2022]
Abstract
During the last two decades, the production of pharmaceutical proteins in plants
evolved from proof of concept to established technology adopted by several biotechnological
companies. This progress is particularly based on intensive research starting stable genetic
transformation and moving to transient expression. Due to its advantages in yield and
speed of protein production transient expression platforms became the leading plant-based
manufacturing technology. Current transient expression methods rely on Agrobacteriummediated
delivery of expression vectors into plant cells. In recent years, great advances have
been made in the improvement of expression vectors, host cell engineering as well as in the
development of commercial manufacturing processes. Several GMP-certified large-scale
production facilities exist around the world to utilize agroinfiltration method. A number of
pharmaceutical proteins produced by transient expression are currently in clinical development.
The great potential of transient expression platform in respect to rapid response to
emerging pandemics was demonstrated by the production of experimental ZMapp antibodies
against Ebola virus as well as influenza vaccines. This review is focused on current design,
status and future perspectives of plant transient expression system for the production
of biopharmaceutical proteins.
Collapse
Affiliation(s)
- Lilya Kopertekh
- Federal Research Centre for Cultivated Plants, Institute for Biosafety in Plant Biotechnology, Erwin-Baur- Str. 27, D-06484, Quedlinburg, Germany
| | - Joachim Schiemann
- Federal Research Centre for Cultivated Plants, Institute for Biosafety in Plant Biotechnology, Erwin-Baur- Str. 27, D-06484, Quedlinburg, Germany
| |
Collapse
|
8
|
Alam A, Jiang L, Kittleson GA, Steadman KD, Nandi S, Fuqua JL, Palmer KE, Tusé D, McDonald KA. Technoeconomic Modeling of Plant-Based Griffithsin Manufacturing. Front Bioeng Biotechnol 2018; 6:102. [PMID: 30087892 PMCID: PMC6066545 DOI: 10.3389/fbioe.2018.00102] [Citation(s) in RCA: 38] [Impact Index Per Article: 6.3] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/23/2018] [Accepted: 07/02/2018] [Indexed: 12/23/2022] Open
Abstract
Griffithsin is a marine algal lectin that exhibits broad-spectrum antiviral activity by binding oligomannose glycans on viral envelope glycoproteins, including those found in HIV-1, HSV-2, SARS, HCV and other enveloped viruses. An efficient, scalable and cost-effective manufacturing process for Griffithsin is essential for the adoption of this drug in human antiviral prophylaxis and therapy, particularly in cost-sensitive indications such as topical microbicides for HIV-1 prevention. The production of certain classes of recombinant biologics in plants can offer scalability, cost and environmental impact advantages over traditional biomanufacturing platforms. Previously, we showed the technical viability of producing recombinant Griffithsin in plants. In this study, we conducted a technoeconomic analysis (TEA) of plant-produced Griffithsin manufactured at commercial launch volumes for use in HIV microbicides. Data derived from multiple non-sequential manufacturing batches conducted at pilot scale and existing facility designs were used to build a technoeconomic model using SuperPro Designer® modeling software. With an assumed commercial launch volume of 20 kg Griffithsin/year for 6.7 million doses of Griffithsin microbicide at 3 mg/dose, a transient vector expression yield of 0.52 g Griffithsin/kg leaf biomass, recovery efficiency of 70%, and purity of >99%, we calculated a manufacturing cost for the drug substance of $0.32/dose and estimated a bulk product cost of $0.38/dose assuming a 20% net fee for a contract manufacturing organization (CMO). This is the first report modeling the manufacturing economics of Griffithsin. The process analyzed is readily scalable and subject to efficiency improvements and could provide the needed market volumes of the lectin within an acceptable range of costs, even for cost-constrained products such as microbicides. The manufacturing process was also assessed for environmental, health and safety impact and found to have a highly favorable environmental output index with negligible risks to health and safety. The results of this study help validate the plant-based manufacturing platform and should assist in selecting preferred indications for Griffithsin as a novel drug.
Collapse
Affiliation(s)
- Aatif Alam
- Department of Chemical Engineering, University of California, Davis, Davis, CA, United States
| | - Linda Jiang
- Department of Chemical Engineering, University of California, Davis, Davis, CA, United States
| | - Gregory A. Kittleson
- Department of Chemical Engineering, University of California, Davis, Davis, CA, United States
| | - Kenneth D. Steadman
- Department of Chemical Engineering, University of California, Davis, Davis, CA, United States
| | - Somen Nandi
- Department of Chemical Engineering, University of California, Davis, Davis, CA, United States
- Global HealthShare Initiative, University of California, Davis, Davis, CA, United States
| | - Joshua L. Fuqua
- Center for Predictive Medicine, University of Louisville, Louisville, KY, United States
| | - Kenneth E. Palmer
- Center for Predictive Medicine, University of Louisville, Louisville, KY, United States
| | - Daniel Tusé
- Intrucept Biomedicine, LLC, Sacramento, CA, United States
| | - Karen A. McDonald
- Department of Chemical Engineering, University of California, Davis, Davis, CA, United States
- Global HealthShare Initiative, University of California, Davis, Davis, CA, United States
| |
Collapse
|
9
|
Espinosa-Leal CA, Puente-Garza CA, García-Lara S. In vitro plant tissue culture: means for production of biological active compounds. PLANTA 2018; 248:1-18. [PMID: 29736623 PMCID: PMC7088179 DOI: 10.1007/s00425-018-2910-1] [Citation(s) in RCA: 166] [Impact Index Per Article: 27.7] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 04/12/2018] [Accepted: 04/27/2018] [Indexed: 05/18/2023]
Abstract
MAIN CONCLUSION Plant tissue culture as an important tool for the continuous production of active compounds including secondary metabolites and engineered molecules. Novel methods (gene editing, abiotic stress) can improve the technique. Humans have a long history of reliance on plants for a supply of food, shelter and, most importantly, medicine. Current-day pharmaceuticals are typically based on plant-derived metabolites, with new products being discovered constantly. Nevertheless, the consistent and uniform supply of plant pharmaceuticals has often been compromised. One alternative for the production of important plant active compounds is in vitro plant tissue culture, as it assures independence from geographical conditions by eliminating the need to rely on wild plants. Plant transformation also allows the further use of plants for the production of engineered compounds, such as vaccines and multiple pharmaceuticals. This review summarizes the important bioactive compounds currently produced by plant tissue culture and the fundamental methods and plants employed for their production.
Collapse
Affiliation(s)
- Claudia A Espinosa-Leal
- Tecnologico de Monterrey, Campus Monterrey, Escuela de Ingeniería y Ciencias, Ave. Eugenio Garza Sada 2501, 64849, Monterrey, NL, México
| | - César A Puente-Garza
- Tecnologico de Monterrey, Campus Monterrey, Escuela de Ingeniería y Ciencias, Ave. Eugenio Garza Sada 2501, 64849, Monterrey, NL, México
| | - Silverio García-Lara
- Tecnologico de Monterrey, Campus Monterrey, Escuela de Ingeniería y Ciencias, Ave. Eugenio Garza Sada 2501, 64849, Monterrey, NL, México.
| |
Collapse
|
10
|
Ma J, Wang Y, Xu N, Jin L, Liu J, Xing S, Li X. Potential large scale production of meningococcal vaccines by stable overexpression of fHbp in the rice seeds. Protein Expr Purif 2018; 152:1-6. [PMID: 29953946 DOI: 10.1016/j.pep.2018.06.014] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/11/2017] [Revised: 06/16/2018] [Accepted: 06/24/2018] [Indexed: 10/28/2022]
Abstract
Factor H binding protein (fHbp) is the most promising vaccine candidate against serogroup B of Neisseria meningitidis which is a major cause of morbidity and mortality in children. In order to facilitate large scale production of a commercial vaccine, we previously used transgenic Arabidopsis thaliana, but plant-derived fHbp is still far away from a commercial vaccine due to less biomass production. Herein, we presented an alternative route for the production of recombinant fHbp from the seeds of transgenic rice. The OsrfHbp gene encoding recombinant fHbp fused protein was introduced into the genome of rice via Agrobacterium-mediated transformation. The both stable integration and transcription of the foreign OsrfHbp were confirmed by Southern blotting and RT-PCR analysis respectively. Further, the expression of fHbp protein was measured by immunoblotting analysis and quantified by ELISA. The results indicated that fHbp was successfully expressed and the highest yield of fHbp was 0.52 ± 0.03% of TSP in the transgenic rice seeds. The purified fHbp protein showed good antigenicity and immunogenicity in the animal model. The results of this experiment offer a novel approach for large-scale production of plant-derived commercial vaccine fHbp.
Collapse
Affiliation(s)
- Jian Ma
- Faculty of Agronomy, Jilin Agricultural University, Changchun, 130118, Jilin, China.
| | - Yunpeng Wang
- Institute of Agricultural Biotechnology, Jilin Academy of Agricultural Sciences, Changchun, 130033, Jilin, China.
| | - Nuo Xu
- College of Life and Environmental Science, Wenzhou University, Wenzhou, 325035, Zhejiang, China.
| | - Libo Jin
- College of Life and Environmental Science, Wenzhou University, Wenzhou, 325035, Zhejiang, China.
| | - Jia Liu
- School of Pharmaceutical Sciences, Changchun University of Chinese Medicine, Changchun, 130117, Jilin, China.
| | - Shaochen Xing
- Institute of Agricultural Biotechnology, Jilin Academy of Agricultural Sciences, Changchun, 130033, Jilin, China; Faculty of Agronomy, Jilin Agricultural University, Changchun, 130118, Jilin, China.
| | - Xiaokun Li
- Faculty of Agronomy, Jilin Agricultural University, Changchun, 130118, Jilin, China; College of Life and Environmental Science, Wenzhou University, Wenzhou, 325035, Zhejiang, China.
| |
Collapse
|
11
|
Abstract
Plant molecular farming depends on a diversity of plant systems for production of useful recombinant proteins. These proteins include protein biopolymers, industrial proteins and enzymes, and therapeutic proteins. Plant production systems include microalgae, cells, hairy roots, moss, and whole plants with both stable and transient expression. Production processes involve a narrowing diversity of bioreactors for cell, hairy root, microalgae, and moss cultivation. For whole plants, both field and automated greenhouse cultivation methods are used with products expressed and produced either in leaves or seeds. Many successful expression systems now exist for a variety of different products with a list of increasingly successful commercialized products. This chapter provides an overview and examples of the current state of plant-based production systems for different types of recombinant proteins.
Collapse
Affiliation(s)
| | - Thomas Bley
- Bioprocess Engineering, Institute of Food Technology and Bioprocess Engineering, TU Dresden, Dresden, Germany
| |
Collapse
|
12
|
Chen TH, Hu CC, Liao JT, Lee YL, Huang YW, Lin NS, Lin YL, Hsu YH. Production of Japanese Encephalitis Virus Antigens in Plants Using Bamboo Mosaic Virus-Based Vector. Front Microbiol 2017; 8:788. [PMID: 28515719 PMCID: PMC5413549 DOI: 10.3389/fmicb.2017.00788] [Citation(s) in RCA: 21] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/04/2017] [Accepted: 04/18/2017] [Indexed: 12/27/2022] Open
Abstract
Japanese encephalitis virus (JEV) is among the major threats to public health in Asia. For disease control and prevention, the efficient production of safe and effective vaccines against JEV is in urgent need. In this study, we produced a plant-made JEV vaccine candidate using a chimeric virus particle (CVP) strategy based on bamboo mosaic virus (BaMV) for epitope presentation. The chimeric virus, designated BJ2A, was constructed by fusing JEV envelope protein domain III (EDIII) at the N-terminus of BaMV coat protein, with an insertion of the foot-and-mouth disease virus 2A peptide to facilitate the production of both unfused and epitope-presenting for efficient assembly of the CVP vaccine candidate. The strategy allowed stable maintenance of the fusion construct over long-term serial passages in plants. Immuno-electron microscopy examination and immunization assays revealed that BJ2A is able to present the EDIII epitope on the surface of the CVPs, which stimulated effective neutralizing antibodies against JEV infection in mice. This study demonstrates the efficient production of an effective CVP vaccine candidate against JEV in plants by the BaMV-based epitope presentation system.
Collapse
Affiliation(s)
- Tsung-Hsien Chen
- Graduate Institute of Biotechnology, National Chung Hsing UniversityTaichung, Taiwan
| | - Chung-Chi Hu
- Graduate Institute of Biotechnology, National Chung Hsing UniversityTaichung, Taiwan
| | - Jia-Teh Liao
- Graduate Institute of Biotechnology, National Chung Hsing UniversityTaichung, Taiwan
| | - Yi-Ling Lee
- Institute of Biomedical Sciences, Academia SinicaTaipei, Taiwan
| | - Ying-Wen Huang
- Graduate Institute of Biotechnology, National Chung Hsing UniversityTaichung, Taiwan
| | - Na-Sheng Lin
- Graduate Institute of Biotechnology, National Chung Hsing UniversityTaichung, Taiwan.,Institute of Plant and Microbial Biology, Academia SinicaTaipei, Taiwan
| | - Yi-Ling Lin
- Institute of Biomedical Sciences, Academia SinicaTaipei, Taiwan
| | - Yau-Heiu Hsu
- Graduate Institute of Biotechnology, National Chung Hsing UniversityTaichung, Taiwan
| |
Collapse
|
13
|
Joung YH, Park SH, Moon KB, Jeon JH, Cho HS, Kim HS. The Last Ten Years of Advancements in Plant-Derived Recombinant Vaccines against Hepatitis B. Int J Mol Sci 2016; 17:E1715. [PMID: 27754367 PMCID: PMC5085746 DOI: 10.3390/ijms17101715] [Citation(s) in RCA: 19] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/26/2016] [Revised: 09/23/2016] [Accepted: 09/29/2016] [Indexed: 12/22/2022] Open
Abstract
Disease prevention through vaccination is considered to be the greatest contribution to public health over the past century. Every year more than 100 million children are vaccinated with the standard World Health Organization (WHO)-recommended vaccines including hepatitis B (HepB). HepB is the most serious type of liver infection caused by the hepatitis B virus (HBV), however, it can be prevented by currently available recombinant vaccine, which has an excellent record of safety and effectiveness. To date, recombinant vaccines are produced in many systems of bacteria, yeast, insect, and mammalian and plant cells. Among these platforms, the use of plant cells has received considerable attention in terms of intrinsic safety, scalability, and appropriate modification of target proteins. Research groups worldwide have attempted to develop more efficacious plant-derived vaccines for over 30 diseases, most frequently HepB and influenza. More inspiring, approximately 12 plant-made antigens have already been tested in clinical trials, with successful outcomes. In this study, the latest information from the last 10 years on plant-derived antigens, especially hepatitis B surface antigen, approaches are reviewed and breakthroughs regarding the weak points are also discussed.
Collapse
Affiliation(s)
- Young Hee Joung
- School of Biological Sciences & Technology, Chonnam National University, Gwangju 61186, Korea.
| | - Se Hee Park
- School of Biological Sciences & Technology, Chonnam National University, Gwangju 61186, Korea.
| | - Ki-Beom Moon
- Molecular Biofarming Research Center, Korea Research Institute of Bioscience & Biotechnology (KRIBB), Daejeon 34141, Korea.
| | - Jae-Heung Jeon
- Molecular Biofarming Research Center, Korea Research Institute of Bioscience & Biotechnology (KRIBB), Daejeon 34141, Korea.
| | - Hye-Sun Cho
- Molecular Biofarming Research Center, Korea Research Institute of Bioscience & Biotechnology (KRIBB), Daejeon 34141, Korea.
| | - Hyun-Soon Kim
- Molecular Biofarming Research Center, Korea Research Institute of Bioscience & Biotechnology (KRIBB), Daejeon 34141, Korea.
| |
Collapse
|
14
|
Wei ZY, Zhang YY, Wang YP, Fan MX, Zhong XF, Xu N, Lin F, Xing SC. Production of Bioactive Recombinant Bovine Chymosin in Tobacco Plants. Int J Mol Sci 2016; 17:E624. [PMID: 27136529 PMCID: PMC4881450 DOI: 10.3390/ijms17050624] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/24/2016] [Revised: 04/11/2016] [Accepted: 04/14/2016] [Indexed: 01/11/2023] Open
Abstract
Chymosin (also known as rennin) plays an essential role in the coagulation of milk in the cheese industry. Chymosin is traditionally extracted from the rumen of calves and is of high cost. Here, we present an alternative method to producing bovine chymosin from transgenic tobacco plants. The CYM gene, which encodes a preprochymosin from bovine, was introduced into the tobacco nuclear genome under control of the viral 35S cauliflower mosaic promoter. The integration and transcription of the foreign gene were confirmed with Southern blotting and reverse transcription PCR (RT-PCR) analyses, respectively. Immunoblotting analyses were performed to demonstrate expression of chymosin, and the expression level was quantified by enzyme-linked immunosorbent assay (ELISA). The results indicated recombinant bovine chymosin was successfully expressed at an average level of 83.5 ng/g fresh weight, which is 0.52% of the total soluble protein. The tobacco-derived chymosin exhibited similar native milk coagulation bioactivity as the commercial product extracted from bovine rumen.
Collapse
Affiliation(s)
- Zheng-Yi Wei
- Agronomy College, Shenyang Agricultural University, No. 120 Dongling Rd., Shenhe Distirct, Shenyang 110866, China.
- Laboratory of Plant Bioreactor and Genetics Engineering, Jilin Provincial Key Laboratory of Agricultural Biotechnology, Agro-Biotechnology Research Institute, Jilin Academy of Agricultural Sciences, No. 1363 Shengtai St., Changchun 130033, China.
| | - Yu-Ying Zhang
- Laboratory of Plant Bioreactor and Genetics Engineering, Jilin Provincial Key Laboratory of Agricultural Biotechnology, Agro-Biotechnology Research Institute, Jilin Academy of Agricultural Sciences, No. 1363 Shengtai St., Changchun 130033, China.
- State Key Labortory of Agrobiotechnology, China Agricultural University, No. 2 West Yuanmingyuan Rd., Beijing 100094, China.
| | - Yun-Peng Wang
- Laboratory of Plant Bioreactor and Genetics Engineering, Jilin Provincial Key Laboratory of Agricultural Biotechnology, Agro-Biotechnology Research Institute, Jilin Academy of Agricultural Sciences, No. 1363 Shengtai St., Changchun 130033, China.
| | - Ming-Xia Fan
- Agronomy College, Shenyang Agricultural University, No. 120 Dongling Rd., Shenhe Distirct, Shenyang 110866, China.
| | - Xiao-Fang Zhong
- Laboratory of Plant Bioreactor and Genetics Engineering, Jilin Provincial Key Laboratory of Agricultural Biotechnology, Agro-Biotechnology Research Institute, Jilin Academy of Agricultural Sciences, No. 1363 Shengtai St., Changchun 130033, China.
| | - Nuo Xu
- Chashan Higher Education Zone, Wenzhou University, Wenzhou 325035, China.
| | - Feng Lin
- Agronomy College, Shenyang Agricultural University, No. 120 Dongling Rd., Shenhe Distirct, Shenyang 110866, China.
| | - Shao-Chen Xing
- Laboratory of Plant Bioreactor and Genetics Engineering, Jilin Provincial Key Laboratory of Agricultural Biotechnology, Agro-Biotechnology Research Institute, Jilin Academy of Agricultural Sciences, No. 1363 Shengtai St., Changchun 130033, China.
| |
Collapse
|
15
|
Nagatoshi Y, Ikeda M, Kishi H, Hiratsu K, Muraguchi A, Ohme-Takagi M. Induction of a dwarf phenotype with IBH1 may enable increased production of plant-made pharmaceuticals in plant factory conditions. PLANT BIOTECHNOLOGY JOURNAL 2016; 14:887-94. [PMID: 26190496 DOI: 10.1111/pbi.12437] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 08/05/2014] [Revised: 06/08/2015] [Accepted: 06/16/2015] [Indexed: 05/05/2023]
Abstract
Year-round production in a contained, environmentally controlled 'plant factory' may provide a cost-effective method to produce pharmaceuticals and other high-value products. However, cost-effective production may require substantial modification of the host plant phenotype; for example, using dwarf plants can enable the growth of more plants in a given volume by allowing more plants per shelf and enabling more shelves to be stacked vertically. We show here that the expression of the chimeric repressor for Arabidopsis AtIBH1 (P35S:AtIBH1SRDX) in transgenic tobacco plants (Nicotiana tabacum) induces a dwarf phenotype, with reduced cell size. We estimate that, in a given volume of cultivation space, we can grow five times more AtIBH1SRDX plants than wild-type plants. Although, the AtIBH1SRDX plants also showed reduced biomass compared with wild-type plants, they produced about four times more biomass per unit of cultivation volume. To test whether the dwarf phenotype affects the production of recombinant proteins, we expressed the genes for anti-hepatitis B virus antibodies (anti-HBs) in tobacco plants and found that the production of anti-HBs per unit fresh weight did not significantly differ between wild-type and AtIBH1SRDX plants. These data indicate that P35S:AtIBH1SRDX plants produced about fourfold more antibody per unit of cultivation volume, compared with wild type. Our results indicate that AtIBH1SRDX provides a useful tool for the modification of plant phenotype for cost-effective production of high-value products by stably transformed plants in plant factory conditions.
Collapse
Affiliation(s)
- Yukari Nagatoshi
- Bioproduction Research Institute, National Institute of Advanced Industrial Science and Technology (AIST), Tsukuba, Ibaraki, Japan
| | - Miho Ikeda
- Bioproduction Research Institute, National Institute of Advanced Industrial Science and Technology (AIST), Tsukuba, Ibaraki, Japan
| | - Hiroyuki Kishi
- Department of Immunology, Graduate School of Medicine and Pharmaceutical Sciences, University of Toyama, Sugitani, Toyama, Japan
| | | | - Atsushi Muraguchi
- Department of Immunology, Graduate School of Medicine and Pharmaceutical Sciences, University of Toyama, Sugitani, Toyama, Japan
| | - Masaru Ohme-Takagi
- Bioproduction Research Institute, National Institute of Advanced Industrial Science and Technology (AIST), Tsukuba, Ibaraki, Japan
- Graduate school of Science and Engineering, Saitama University, Saitama, Japan
| |
Collapse
|
16
|
Alkanaimsh S, Karuppanan K, Guerrero A, Tu AM, Hashimoto B, Hwang MS, Phu ML, Arzola L, Lebrilla CB, Dandekar AM, Falk BW, Nandi S, Rodriguez RL, McDonald KA. Transient Expression of Tetrameric Recombinant Human Butyrylcholinesterase in Nicotiana benthamiana. FRONTIERS IN PLANT SCIENCE 2016; 7:743. [PMID: 27379103 PMCID: PMC4909763 DOI: 10.3389/fpls.2016.00743] [Citation(s) in RCA: 25] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Received: 12/15/2015] [Accepted: 05/17/2016] [Indexed: 05/08/2023]
Abstract
To optimize the expression, extraction and purification of plant-derived tetrameric recombinant human butyrylcholinesterase (prBChE), we describe the development and use of plant viral amplicon-based gene expression system; Tobacco Mosaic Virus (TMV) RNA-based overexpression vector (TRBO) to express enzymatically active FLAG-tagged plant made recombinant butyrylcholinesterase (rBChE) in Nicotiana benthamiana leaves using transient agroinfiltration. Two gene expression cassettes were designed to express the recombinant protein in either the ER or to the apoplastic compartment. Leaf homogenization was used to isolate ER-retained recombinant butyrylcholinesterase (prBChE-ER) while apoplast-targeted rBChE was isolated by either leaf homogenization (prBChE) or vacuum-extraction of apoplastic wash fluid (prBChE-AWF). rBChE from apoplast wash fluid had a higher specific activity but lower enzyme yield than leaf homogenate. To optimize the isolation and purification of total recombinant protein from leaf homogenates, an acidic extraction buffer was used. The acidic extraction buffer yielded >95% enzymatically active tetrameric rBChE as verified by Coomassie stained and native gel electrophoresis. Furthermore, when compared to human butyrylcholinesterase, the prBChE was found to be similar in terms of tetramerization and enzyme kinetics. The N-linked glycan profile of purified prBChE-ER was found to be mostly high mannose structures while the N-linked glycans on prBChE-AWF were primarily complex. The glycan profile of the prBChE leaf homogenates showed a mixture of high mannose, complex and paucimannose type N-glycans. These findings demonstrate the ability of plants to produce rBChE that is enzymatically active and whose oligomeric state is comparable to mammalian butyrylcholinesterase. The process of plant made rBChE tetramerization and strategies for improving its pharmacokinetics properties are also discussed.
Collapse
Affiliation(s)
- Salem Alkanaimsh
- Department of Chemical Engineering, University of California, DavisDavis, CA, USA
| | - Kalimuthu Karuppanan
- Department of Chemical Engineering, University of California, DavisDavis, CA, USA
| | - Andrés Guerrero
- Department of Chemistry, University of California, DavisDavis, CA, USA
| | - Aye M. Tu
- Department of Plant Science, University of California, DavisDavis, CA, USA
| | - Bryce Hashimoto
- Department of Chemical Engineering, University of California, DavisDavis, CA, USA
| | - Min Sook Hwang
- Department of Plant Pathology, University of California, DavisDavis, CA, USA
| | - My L. Phu
- Department of Plant Science, University of California, DavisDavis, CA, USA
| | - Lucas Arzola
- Department of Chemical Engineering, University of California, DavisDavis, CA, USA
| | | | - Abhaya M. Dandekar
- Department of Plant Science, University of California, DavisDavis, CA, USA
| | - Bryce W. Falk
- Department of Plant Pathology, University of California, DavisDavis, CA, USA
| | - Somen Nandi
- Department of Molecular and Cellular Biology, University of California, DavisDavis, CA, USA
- Department of Global HealthShare Initiative, University of California, DavisDavis, CA, USA
| | - Raymond L. Rodriguez
- Department of Molecular and Cellular Biology, University of California, DavisDavis, CA, USA
- Department of Global HealthShare Initiative, University of California, DavisDavis, CA, USA
| | - Karen A. McDonald
- Department of Chemical Engineering, University of California, DavisDavis, CA, USA
- Department of Global HealthShare Initiative, University of California, DavisDavis, CA, USA
- *Correspondence: Karen A. McDonald,
| |
Collapse
|
17
|
Łojewska E, Kowalczyk T, Olejniczak S, Sakowicz T. Extraction and purification methods in downstream processing of plant-based recombinant proteins. Protein Expr Purif 2015; 120:110-7. [PMID: 26742898 DOI: 10.1016/j.pep.2015.12.018] [Citation(s) in RCA: 19] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/25/2015] [Revised: 12/23/2015] [Accepted: 12/24/2015] [Indexed: 01/02/2023]
Abstract
During the last two decades, the production of recombinant proteins in plant systems has been receiving increased attention. Currently, proteins are considered as the most important biopharmaceuticals. However, high costs and problems with scaling up the purification and isolation processes make the production of plant-based recombinant proteins a challenging task. This paper presents a summary of the information regarding the downstream processing in plant systems and provides a comprehensible overview of its key steps, such as extraction and purification. To highlight the recent progress, mainly new developments in the downstream technology have been chosen. Furthermore, besides most popular techniques, alternative methods have been described.
Collapse
Affiliation(s)
- Ewelina Łojewska
- Department of Genetics and Plant Molecular Biology and Biotechnology, The University of Lodz, Banacha Street 12/16, 90-237 Lodz, Poland.
| | - Tomasz Kowalczyk
- Department of Genetics and Plant Molecular Biology and Biotechnology, The University of Lodz, Banacha Street 12/16, 90-237 Lodz, Poland
| | - Szymon Olejniczak
- Department of Genetics and Plant Molecular Biology and Biotechnology, The University of Lodz, Banacha Street 12/16, 90-237 Lodz, Poland
| | - Tomasz Sakowicz
- Department of Genetics and Plant Molecular Biology and Biotechnology, The University of Lodz, Banacha Street 12/16, 90-237 Lodz, Poland
| |
Collapse
|
18
|
Thomas DR, Walmsley AM. The effect of the unfolded protein response on the production of recombinant proteins in plants. PLANT CELL REPORTS 2015; 34:179-87. [PMID: 25187294 DOI: 10.1007/s00299-014-1680-x] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 07/10/2014] [Revised: 08/21/2014] [Accepted: 08/26/2014] [Indexed: 05/16/2023]
Abstract
Recombinant proteins are currently produced through a wide variety of host systems, including yeast, E. coli, insect and mammalian cells. One of the most recent systems developed uses plant cells. While considerable advances have been made in the yields and fidelity of plant-made recombinant proteins, many of these gains have arisen from the development of recombinant factors. This includes elements such as highly effective promoters and untranslated regions, deconstructed viral vectors, silencing inhibitors, and improved DNA delivery techniques. However, unlike other host systems, much of the work on recombinant protein production in plants uses wild-type hosts that have not been modified to facilitate recombinant protein expression. As such, there are still endogenous mechanisms functioning to maintain the health of the cell. The result is that these pathways, such as the unfolded protein response, can actively work to reduce recombinant protein production to maintain the integrity of the cell. This review examines how issues arising from the unfolded protein response have been addressed in other systems, and how these methods may be transferable to plant systems. We further identify several areas of host plant biology that present attractive targets for modification to facilitate recombinant protein production.
Collapse
Affiliation(s)
- David Rhys Thomas
- School of Biological Sciences, Monash University, Clayton, VIC, 3800, Australia,
| | | |
Collapse
|
19
|
Permyakova NV, Uvarova EA, Deineko EV. State of research in the field of the creation of plant vaccines for veterinary use. RUSSIAN JOURNAL OF PLANT PHYSIOLOGY: A COMPREHENSIVE RUSSIAN JOURNAL ON MODERN PHYTOPHYSIOLOGY 2015; 62:23-38. [PMID: 32214753 PMCID: PMC7089518 DOI: 10.1134/s1021443715010100] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Received: 06/27/2014] [Indexed: 06/08/2023]
Abstract
Transgenic plants as an alternative of costly systems of recombinant immunogenic protein expression are the source for the production of cheap and highly efficient biotherapeuticals of new generation, including plant vaccines. In the present review, possibilities of plant system application for the production of recombinant proteins for veterinary use are considered, the history of the "edible vaccine" concept is briefly summarized, advantages and disadvantages of various plant systems for the expression of recombinant immunogenic proteins are discussed. The list of recombinant plant vaccines for veterinary use, which are at different stages of clinical trials, is presented.
Collapse
Affiliation(s)
- N. V. Permyakova
- Institute of Cytology and Genetics, Rusian Academy of Sciences, Siberian Branch, pr. Lavrent’eva 10, Novosibirsk, 630090 Russia
| | - E. A. Uvarova
- Institute of Cytology and Genetics, Rusian Academy of Sciences, Siberian Branch, pr. Lavrent’eva 10, Novosibirsk, 630090 Russia
| | - E. V. Deineko
- Institute of Cytology and Genetics, Rusian Academy of Sciences, Siberian Branch, pr. Lavrent’eva 10, Novosibirsk, 630090 Russia
| |
Collapse
|
20
|
Walwyn DR, Huddy SM, Rybicki EP. Techno-economic analysis of horseradish peroxidase production using a transient expression system in Nicotiana benthamiana. Appl Biochem Biotechnol 2015; 175:841-54. [PMID: 25344434 DOI: 10.1007/s12010-014-1320-5] [Citation(s) in RCA: 36] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/01/2014] [Accepted: 10/15/2014] [Indexed: 12/19/2022]
Abstract
Despite the advantages of plant-based transient expression systems relative to microbial or mammalian cell systems, the commercial production of recombinant proteins using plants has not yet been achieved to any significant extent. One of the challenges has been the lack of published data on the costs of manufacture for products other than biopharmaceuticals. In this study, we report on the techno-economic analysis of the production of a standard commercial enzyme, namely, horseradish peroxidase (HRP), using a transient expression system in Nicotiana benthamiana. Based on the proven plant yield of 240 mg HRP/kg biomass, a biomass productivity of 15-kg biomass/m(2)/year and a process yield of 54 % (mg HRP product/mg HRP in biomass), it is apparent that HRP can be manufactured economically via transient expression in plants in a large-scale facility (>5 kg HRP/year). At this level, the process is competitive versus the existing technology (extraction of the enzyme from horseradish), and the product is of comparable or improved activity, containing only the preferred isoenzyme C. Production scale, protein yield and biomass productivity are found to be the most important determinants of overall viability.
Collapse
Affiliation(s)
- David Richard Walwyn
- Department of Engineering and Technology Management, University of Pretoria, Pretoria, 0002, Gauteng, South Africa,
| | | | | |
Collapse
|
21
|
Tusé D, Tu T, McDonald KA. Manufacturing economics of plant-made biologics: case studies in therapeutic and industrial enzymes. BIOMED RESEARCH INTERNATIONAL 2014; 2014:256135. [PMID: 24977145 PMCID: PMC4058100 DOI: 10.1155/2014/256135] [Citation(s) in RCA: 116] [Impact Index Per Article: 11.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 12/07/2013] [Accepted: 02/28/2014] [Indexed: 11/17/2022]
Abstract
Production of recombinant biologics in plants has received considerable attention as an alternative platform to traditional microbial and animal cell culture. Industrially relevant features of plant systems include proper eukaryotic protein processing, inherent safety due to lack of adventitious agents, more facile scalability, faster production (transient systems), and potentially lower costs. Lower manufacturing cost has been widely claimed as an intuitive feature of the platform by the plant-made biologics community, even though cost information resides within a few private companies and studies accurately documenting such an advantage have been lacking. We present two technoeconomic case studies representing plant-made enzymes for diverse applications: human butyrylcholinesterase produced indoors for use as a medical countermeasure and cellulases produced in the field for the conversion of cellulosic biomass into ethanol as a fuel extender. Production economics were modeled based on results reported with the latest-generation expression technologies on Nicotiana host plants. We evaluated process unit operations and calculated bulk active and per-dose or per-unit costs using SuperPro Designer modeling software. Our analyses indicate that substantial cost advantages over alternative platforms can be achieved with plant systems, but these advantages are molecule/product-specific and depend on the relative cost-efficiencies of alternative sources of the same product.
Collapse
Affiliation(s)
- Daniel Tusé
- Intrucept Biomedicine LLC, 2695 13th Street, Sacramento, CA 95818, USA
| | - Tiffany Tu
- Department of Chemical Engineering and Materials Science, University of California, 1 Shields Avenue, Davis, CA 95616, USA
| | - Karen A. McDonald
- Department of Chemical Engineering and Materials Science, University of California, 1 Shields Avenue, Davis, CA 95616, USA
| |
Collapse
|
22
|
Magnusdottir A, Vidarsson H, Björnsson JM, Örvar BL. Barley grains for the production of endotoxin-free growth factors. Trends Biotechnol 2013; 31:572-80. [DOI: 10.1016/j.tibtech.2013.06.002] [Citation(s) in RCA: 22] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/10/2013] [Revised: 06/11/2013] [Accepted: 06/12/2013] [Indexed: 02/07/2023]
|
23
|
Virgili-López G, Langhans M, Bubeck J, Pedrazzini E, Gouzerh G, Neuhaus JM, Robinson DG, Vitale A. Comparison of membrane targeting strategies for the accumulation of the human immunodeficiency virus p24 protein in transgenic tobacco. Int J Mol Sci 2013; 14:13241-65. [PMID: 23803657 PMCID: PMC3742185 DOI: 10.3390/ijms140713241] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/07/2013] [Revised: 05/28/2013] [Accepted: 06/17/2013] [Indexed: 01/09/2023] Open
Abstract
Membrane anchorage was tested as a strategy to accumulate recombinant proteins in transgenic plants. Transmembrane domains of different lengths and topology were fused to the cytosolic HIV antigen p24, to promote endoplasmic reticulum (ER) residence or traffic to distal compartments of the secretory pathway in transgenic tobacco. Fusions to a domain of the maize seed storage protein γ-zein were also expressed, as a reference strategy that leads to very high stability via the formation of large polymers in the ER lumen. Although all the membrane anchored constructs were less stable compared to the zein fusions, residence at the ER membrane either as a type I fusion (where the p24 sequence is luminal) or a tail-anchored fusion (where the p24 sequence is cytosolic) resulted in much higher stability than delivery to the plasma membrane or intermediate traffic compartments. Delivery to the tonoplast was never observed. The inclusion of a thrombin cleavage site allowed for the quantitative in vitro recovery of p24 from all constructs. These results point to the ER as suitable compartment for the accumulation of membrane-anchored recombinant proteins in plants.
Collapse
Affiliation(s)
- Goretti Virgili-López
- Department of Plant Cell Biology, Centre for Organismal Studies, University of Heidelberg, Heidelberg D-69120, Germany; E-Mails: (G.V.-L.); (M.L.); (J.B.)
- Institute of Agricultural Biology and Biotechnology, National Research Council (CNR), via Bassini 15, Milano 20133, Italy; E-Mail:
- Laboratory of Cell and Molecular Biology, University of Neuchatel, Rue Emile-Argand 11, Neuchâtel CH-2000, Switzerland; E-Mail:
| | - Markus Langhans
- Department of Plant Cell Biology, Centre for Organismal Studies, University of Heidelberg, Heidelberg D-69120, Germany; E-Mails: (G.V.-L.); (M.L.); (J.B.)
| | - Julia Bubeck
- Department of Plant Cell Biology, Centre for Organismal Studies, University of Heidelberg, Heidelberg D-69120, Germany; E-Mails: (G.V.-L.); (M.L.); (J.B.)
| | - Emanuela Pedrazzini
- Institute of Agricultural Biology and Biotechnology, National Research Council (CNR), via Bassini 15, Milano 20133, Italy; E-Mail:
| | - Guillaume Gouzerh
- Laboratory of Cell and Molecular Biology, University of Neuchatel, Rue Emile-Argand 11, Neuchâtel CH-2000, Switzerland; E-Mail:
| | - Jean-Marc Neuhaus
- Laboratory of Cell and Molecular Biology, University of Neuchatel, Rue Emile-Argand 11, Neuchâtel CH-2000, Switzerland; E-Mail:
| | - David G. Robinson
- Department of Plant Cell Biology, Centre for Organismal Studies, University of Heidelberg, Heidelberg D-69120, Germany; E-Mails: (G.V.-L.); (M.L.); (J.B.)
| | - Alessandro Vitale
- Institute of Agricultural Biology and Biotechnology, National Research Council (CNR), via Bassini 15, Milano 20133, Italy; E-Mail:
| |
Collapse
|
24
|
Nausch H, Mischofsky H, Koslowski R, Meyer U, Broer I, Huckauf J. Expression and subcellular targeting of human complement factor C5a in Nicotiana species. PLoS One 2012; 7:e53023. [PMID: 23285250 PMCID: PMC3532468 DOI: 10.1371/journal.pone.0053023] [Citation(s) in RCA: 19] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/01/2012] [Accepted: 11/22/2012] [Indexed: 01/10/2023] Open
Abstract
We evaluated transgenic tobacco plants as an alternative to Escherichia coli for the production of recombinant human complement factor 5a (C5a). C5a has not been expressed in plants before and is highly unstable in vivo in its native form, so it was necessary to establish the most suitable subcellular targeting strategy. We used the strong and constitutive CaMV 35S promoter to drive transgene expression and compared three different subcellular compartments. The yields of C5a in the T(0) transgenic plants were low in terms of the proportion of total soluble protein (TSP) when targeted to the apoplast (0.0002% TSP) or endoplasmic reticulum (0.0003% TSP) but was one order of magnitude higher when targeted to the vacuole (0.001% TSP). The yields could be increased by conventional breeding (up to 0.014% TSP in the T₂ generation). C5a accumulated to the same level in seeds and leaves when targeted to the apoplast but was up to 1.7-fold more abundant in the seeds when targeted to the ER or vacuole, although this difference was less striking in the better-performing lines. When yields were calculated as an amount per gram fresh weight of transgenic plant tissue, the vacuole targeting strategy was clearly more efficient in seeds, reaching 35.8 µg C5a per gram of fresh seed weight compared to 10.62 µg C5a per gram fresh weight of leaves. Transient expression of C5aER and C5aVac in N. benthamiana, using MagnICON vectors, reached up to 0.2% and 0.7% of TSP, respectively, but was accompanied by cytotoxic effects and induced leaf senescence. Western blot of the plant extracts revealed a band matching the corresponding glycosylated native protein and the bioassay demonstrated that recombinant C5a was biologically active.
Collapse
Affiliation(s)
- Henrik Nausch
- Department of Agrobiotechnology, Agricultural and Environmental Faculty, University of Rostock, Rostock, Germany
| | - Heike Mischofsky
- Department of Agrobiotechnology, Agricultural and Environmental Faculty, University of Rostock, Rostock, Germany
| | | | | | - Inge Broer
- Department of Agrobiotechnology, Agricultural and Environmental Faculty, University of Rostock, Rostock, Germany
| | - Jana Huckauf
- Department of Agrobiotechnology, Agricultural and Environmental Faculty, University of Rostock, Rostock, Germany
| |
Collapse
|
25
|
Naik AD, Menegatti S, Reese HR, Gurgel PV, Carbonell RG. Process for purification of monoclonal antibody expressed in transgenic Lemna plant extract using dextran-coated charcoal and hexamer peptide affinity resin. J Chromatogr A 2012; 1260:61-6. [PMID: 22981461 DOI: 10.1016/j.chroma.2012.08.043] [Citation(s) in RCA: 26] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/04/2012] [Revised: 08/07/2012] [Accepted: 08/12/2012] [Indexed: 10/28/2022]
Abstract
The production of therapeutic proteins using transgenic plants offers several advantages, including low production cost, absence of human pathogens, presence of glycosylation mechanisms, and the ability to fold complex therapeutic proteins into their proper conformation. However, impurities such as phenolic compounds and pigments encountered during purification are quite different from those faced during purification from mammalian cell culture supernatants. This paper deals with the development of a pretreatment and affinity separation process for the purification of a monoclonal antibody from transgenic Lemna plant extract. A pretreatment step is described using dextran-coated charcoal for the removal of pigments and phenolic compounds without reducing the antibody concentration. Then, the peptide affinity ligand HWRGWV coupled to a commercial polymethacrylate resin is used for the capture and purification of MAb from the pretreated plant extract. The final yield and purity of the MAb obtained were 90% and 96% respectively. The performance of the hexamer peptide resin after the pretreatment step was found to be similar to that obtained with a commercial Protein A resin.
Collapse
Affiliation(s)
- Amith D Naik
- Department of Chemical and Biomolecular Engineering, North Carolina State University, 911 Partners Way, Raleigh, NC 27695-7095, USA
| | | | | | | | | |
Collapse
|
26
|
Zhang S, Sherwood RW, Yang Y, Fish T, Chen W, McCardle JA, Jones RM, Yusibov V, May ER, Rose JKC, Thannhauser TW. Comparative characterization of the glycosylation profiles of an influenza hemagglutinin produced in plant and insect hosts. Proteomics 2012; 12:1269-88. [PMID: 22577028 PMCID: PMC4545245 DOI: 10.1002/pmic.201100474] [Citation(s) in RCA: 40] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/11/2011] [Accepted: 01/01/2012] [Indexed: 11/11/2022]
Abstract
The main objective of this study was to characterize the N-linked glycosylation profiles of recombinant hemagglutinin (HA) proteins expressed in either insect or plant hosts, and to develop a mass spectrometry based workflow that can be used in quality control to assess batch-to-batch reproducibility for recombinant HA glycosylation. HA is a surface glycoprotein of the influenza virus that plays a key role in viral infectivity and pathogenesis. Characterization of the glycans for plant recombinant HA from the viral strain A/California/04/09 (H1N1) has not yet been reported. In this study, N-linked glycosylation patterns of the recombinant HAs from both insect and plant hosts were characterized by precursor ion scan-driven data-dependent analysis followed by high-resolution MS/MS analysis of the deglycosylated tryptic peptides. Five glycosylation sites (N11, N23, N276, N287, and N481) were identified containing high mannose type glycans in plant-expressed HAs, and complex type glycoforms for the insect-expressed HA. More than 95% site occupancy was observed for all glycosylation sites except N11, which was 60% occupied. Multiple-reaction monitoring based quantitation analysis was developed for each glycopeptide isoform and the quantitative results indicate that the Man(8) GlcNAc(2) is the dominant glycan for all sites in plant-expressed HAs. The relative abundance of the glycoforms at each specific glycosylation site and the relative quantitation for each glycoform among three HAs were determined. Few differences in the glycosylation profiles were detected between the two batches of plant HAs studied, but there were significant differences between the glycosylation patterns in the HAs generated in plant and insect expression hosts.
Collapse
Affiliation(s)
- Sheng Zhang
- Institute for Biotechnology and Life Science Biotechnologies, Cornell University, Ithaca, NY 14853, USA.
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|